

**Amendments to the Claims.**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously presented) In a composition which comprises a radiopharmaceutical in a container which has a silica coating on the inner surface, the improvement being that the radiopharmaceutical comprises a coordination complex of formula  $ML_n$ ,

wherein:

M is the radiometal of the radiopharmaceutical,

L is an organic ligand, which is carbon-containing chelating agent which comprises 2, 3, 4, 5, 6 or 8 heteroatoms suitable for coordination to M, wherein each heteroatom is independently chosen from N, O, S, P or Se;

n is number of ligands (L) attached to M and is an integer of value 1 to 8.

2. (Previously presented) The composition of claim 1 wherein the radiopharmaceutical is a liquid or solution.

3. (Previously presented) The composition of claim 1 wherein M is  $^{111}\text{In}$  or  $^{99m}\text{Tc}$ .

4. (Previously presented) The composition of claim 1 wherein the silica coating is deposited by a PCVD process.

5. (Previously presented) The composition of claim 1 wherein the container is a glass vial with a closure.

6. (Currently amended) A kit for the preparation of a sterile radiopharmaceutical metal complex which comprises ~~a non-radioactive~~ an organic ligand composition in a container which has a silica coating on the inner surface, wherein said ligand (L) is as defined in claim 1.

7. (Previously presented) The kit of claim 6 wherein the metal complex is a  $^{99m}\text{Tc}$  complex.
8. (Currently Amended) The kit of claim 6 wherein the ~~non-radioactive~~ organic ligand composition is lyophilized.
9. (Previously presented) The kit of claim 6 wherein the silica coating is deposited by a PCVD process.
10. (Previously presented) A composition for the preparation of a stabilized radiopharmaceutical metal complex of formula  $\text{ML}_n$  wherein said composition comprises:
  - (i) a stabilizer capable of stabilizing said radiopharmaceutical metal complex;  
and
  - (ii) an organic ligand (L) which forms a coordination complex with the radiometal (M),  
in a container which has a silica coating on the inner surface;  
wherein M, L and n are as defined in claim 1.
11. (Previously presented) The composition of claim 10, which further comprises a bacteriostat suitable for use with a radiopharmaceutical metal complex.
12. (Previously presented) The composition of claim 11, wherein the bacteriostat comprises a paraben.
13. (Previously presented) The composition of claim 10 wherein M is  $^{111}\text{In}$  or  $^{99m}\text{Tc}$ .
14. (Previously presented) The composition of claim 10 wherein the silica coating is deposited by a PCVD process.